FDA Revokes EUA For GSK’s COVID-19 Antibody In All U.S. Regions

FDA on Tuesday (April 5) revoked emergency use authorization for GlaxoSmithKline’s COVID-19 monoclonal antibody sotrovimab in all U.S. states and territories in light of Centers for Disease Control and Prevention data that show the BA.2 subvariant of Omicron now comprises 72% of cases in the United States. FDA says sotrovimab likely will not work against BA.2. The agency has slowly pulled back sotrovimab’s EUA over the past couple of weeks as the number of BA.2 cases has risen. On March...